EMA/304164/2012

European Medicines Agency decision

P/0084/2012

of 21 May 2012

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for liraglutide (Victoza) (EMEA-000128-PIP02-09) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8670
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

European Medicines Agency decision

P/0084/2012

of 21 May 2012

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for liraglutide (Victoza) (EMEA-000128-PIP02-09) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Novo Nordisk A/S on 24 August 2009 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 11 May 2012, in accordance with Article 18 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency, following a re-examination procedure of the Paediatric Committee's opinion according to Article 25(3) of Regulation (EC) No 1901/2006, has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for liraglutide (Victoza), solution for injection (pre-filled pen), subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for liraglutide (Victoza), solution for injection (pre-filled pen), subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for liraglutide (Victoza), solution for injection (pre-filled pen), subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This agreed PIP covers all conditions, indications, pharmaceutical forms, routes of administration, measures, timelines, waivers and deferrals, as agreed in the decision P/105/2008 issued on 28 November 2008, including subsequent modifications thereof.

Article 5

This decision is addressed to Novo Nordisk A/S, Novo Alle, DK-2880 Bagsværd, Denmark.

Done at London, 21 May 2012

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/266178/2012

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation plan and a deferral and a waiver (after re-examination)

EMEA-000128-PIP02-09

Scope of the application

Active substance(s):

Liraglutide

Invented name:

Victoza

Condition(s):

Treatment of obesity

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Solution for injection (pre-filled pen)

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Novo Nordisk A/S

Information about the authorised medicinal product:

See Annex II

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Novo Nordisk A/S submitted for agreement to the European Medicines Agency on 24 August 2009 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

An Opinion was adopted by the Paediatric Committee on 9 March 2012 for the above mentioned product. Novo Nordisk A/S received the Paediatric Committee Opinion on 16 March 2012.

On 12 April 2012 Novo Nordisk A/S submitted to the European Medicines Agency a written request, including detailed grounds for re-examination of the Opinion.

The re-examination procedure started on 13 April 2012.

Final Opinion

1. The Paediatric Committee, having assessed the detailed grounds for re-examination, in accordance with Article 25(3) of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

    1.1. to revise its opinion and to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,

    1.2. following re-examination, to amend the timelines of the paediatric investigation plan and the timelines of the deferral.

    The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix(ces).

London, 11 May 2012

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: Treatment of obesity

The waiver applies to:

- The paediatric population from birth to less than 2 years of age;
- for solution for injection (prefilled pen), for subcutaneous use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset.

and to:

- The paediatric population from 2 to less than 6 years of age;
- for solution for injection (prefilled pen), for subcutaneous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric Investigation Plan

2.1. Condition: Treatment of obesity

2.1.1. Indication(s) targeted by the PIP

Treatment of obesity

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Solution for injection (prefilled pen).

2.1.4. Studies

Area	Number of studies	Description
Quality	1	**Study 1** A prefilled pen or other device which can deliver discrete dosages of 0.3 mg must be made available for paediatric use.
Non-clinical	1	**Study 2** 6-week juvenile repeat dose toxicity study in rats, including dose range finding, to investigate potential harmful effects on the developing nervous system and on sexual maturation.

Area	Number of studies	Description
Clinical	5	**Study 3** Randomised, double-blind, placebo-controlled, multi-centre trial to evaluate tolerability, safety, pharmacokinetics and pharmacodynamics in obese children aged 12 to less than 18 years and Tanner stages 2–5 pubertal development. **Study 4** Randomised, double-blind, placebo-controlled, multicentre trial with an open label and subsequent follow-up period off drug evaluating the efficacy and safety of liraglutide in conjunction with lifestyle modifications for weight loss (structured diet and exercise programme, counselling) in obese adolescents aged 12 to less than 18 years and Tanner stages 2–5 pubertal development. **Study 5** Randomised, double-blind, placebo-controlled, multi-centre trial to evaluate tolerability, safety, pharmacokinetics and pharmacodynamics in obese children aged 6 to less than 12 years and Tanner stage below 2. **Study 6** Randomised, double-blind, placebo-controlled, multicentre trial with an open label and follow-up period evaluating the efficacy and safety of liraglutide in conjunction with lifestyle modifications for weight loss (structured diet and exercise programme, counselling) in obese children with Prader Willi Syndrome (PWS); age staggered entry, part A: from 12 to 18 years and Tanner stage 2 and above, part B: from 6 to less than 12 years and Tanner stage below 2. **Study 7** Randomised, double-blind, placebo-controlled, multicentre trial with an open label and follow-up period evaluating the efficacy and safety of liraglutide in conjunction with lifestyle modifications for weight loss (structured diet and exercise programme, counselling) in obese children, aged 6 to less than 12 years and Tanner stage below 2.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By August 2023
Deferral for one or more studies contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of Diabetes Mellitus, Type 2

   Authorised indications:

Victoza is indicated for treatment of adults with type 2 diabetes mellitus to achieve glycaemic control:

In combination with:

- Metformin or a sulphonylurea, in patients with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin or sulphonylurea.

In combination with:

- Metformin and a sulphonylurea or metformin and a thiazolidinedione in patients with insufficient glycaemic control despite dual therapy.

EU Number	**Invented name**	**Strength**	**Pharmaceu-tical form**	**Route of administra-tion**	**Packaging**	**Content (concent-ration)**	**Package size**
EU/1/09/529/001	Victoza	6 mg/ml	Solution for injection in pre-filled pen	Subcutaneous use	cartridge (glass) in pre-filled pen	3.0 ml	1 pre-filled pen
EU/1/09/529/002	Victoza	6 mg/ml	Solution for injection in pre-filled pen	Subcutaneous use	cartridge (glass) in pre-filled pen	3.0 ml	2 pre-filled pen
EU/1/09/529/003	Victoza	6 mg/ml	Solution for injection in pre-filled pen	Subcutaneous use	cartridge (glass) in pre-filled pen	3.0 ml	3 pre-filled pen
EU/1/09/529/004	Victoza	6 mg/ml	Solution for injection in pre-filled pen	Subcutaneous use	cartridge (glass) in pre-filled pen	3.0 ml	5 pre-filled pen
EU/1/09/529/005	Victoza	6 mg/ml	Solution for injection in pre-filled pen	Subcutaneous use	cartridge (glass) in pre-filled pen	3.0 ml	10 pre-filled pen